GLPwatch
Incretin hormones and the satiation signal.
Int J Obes (Lond) · 2013
Last updated 2026-05-28Research shows that GLP-1, a hormone that helps regulate appetite, may be less effective in people with obesity. Two approved diabetes drugs, exenatide and liraglutide, which mimic GLP-1, have been found to help people lose weight in studies, suggesting they could be a treatment option for obesity.
AI summary of the abstract below.
| Journal | Int J Obes (Lond), 2013 |
|---|---|
| Citations | 130 |
| Relative citation ratio | 4.61 |
| NIH percentile | 91 |
| Molecules | — |
| Conditions studied | Obesity, Type 2 Diabetes |
Abstract
Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.
Verbatim abstract via PubMed 23295502 ↗